- Home
- ADBE vs SNY Comparison
ADBE vs SNY Comparison
Compare ADBE & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADBE
- SNY
- Stock Information
- Founded
- ADBE 1982
- SNY 1994
- Country
- ADBE United States
- SNY France
- Employees
- ADBE N/A
- SNY N/A
- Industry
- ADBE Computer Software: Prepackaged Software
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- ADBE Technology
- SNY Health Care
- Exchange
- ADBE Nasdaq
- SNY Nasdaq
- Market Cap
- ADBE 136.1B
- SNY 116.1B
- IPO Year
- ADBE 1986
- SNY N/A
- Fundamental
- Price
- ADBE $319.28
- SNY $49.54
- Analyst Decision
- ADBE Buy
- SNY Buy
- Analyst Count
- ADBE 23
- SNY 4
- Target Price
- ADBE $457.48
- SNY $61.50
- AVG Volume (30 Days)
- ADBE 3.4M
- SNY 2.3M
- Earning Date
- ADBE 12-10-2025
- SNY 10-24-2025
- Dividend Yield
- ADBE N/A
- SNY 3.23%
- EPS Growth
- ADBE 35.82
- SNY 105.93
- EPS
- ADBE 16.05
- SNY 8.67
- Revenue
- ADBE $23,181,000,000.00
- SNY $53,890,648,839.00
- Revenue This Year
- ADBE $12.33
- SNY $2.37
- Revenue Next Year
- ADBE $9.26
- SNY $6.51
- P/E Ratio
- ADBE $19.82
- SNY $5.71
- Revenue Growth
- ADBE 10.66
- SNY N/A
- 52 Week Low
- ADBE $315.18
- SNY $44.62
- 52 Week High
- ADBE $557.90
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- ADBE 33.13
- SNY 44.65
- Support Level
- ADBE $323.03
- SNY $48.55
- Resistance Level
- ADBE $340.00
- SNY $52.67
- Average True Range (ATR)
- ADBE 6.67
- SNY 0.73
- MACD
- ADBE -1.24
- SNY -0.09
- Stochastic Oscillator
- ADBE 13.75
- SNY 23.94
About ADBE Adobe Inc.
Adobe provides content creation, document management, and digital marketing and advertising software and services to creative professionals and marketers for creating, managing, delivering, measuring, optimizing, and engaging with compelling content multiple operating systems, devices, and media. The company operates with three segments: digital media content creation, digital experience for marketing solutions, and publishing for legacy products (less than 5% of revenue).
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.